Evaluation of [89Zr]Zr-girentuximab PET imaging of clear cell renal cell carcinoma in Chinese patients: a Phase 1 clinical study (ZIRDOSE-CP)
Abstract Background Results from a multinational Phase 3 study demonstrated high accuracy and a favorable safety and tolerability profile of [89Zr]Zr-girentuximab PET for detection and characterization of clear cell renal cell carcinoma (ccRCC). However, [89Zr]Zr-girentuximab has not been studied in...
Збережено в:
| Автори: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
SpringerOpen
2025-12-01
|
| Серія: | EJNMMI Research |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1186/s13550-025-01332-5 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|